Timothy Vartanian

List of Publications by Year
in descending order

22	740	687363 13	677142 22
papers	citations	h-index	g-index

22	22	22	1183
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease. PLoS ONE, 2013, 8, e76359.	2.5	169
2	Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination. MBio, 2015, 6, e02513.	4.1	71
3	The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens Îµ-Toxin. PLoS Pathogens, 2015, 11, e1004896.	4.7	69
4	Nna1 Mediates Purkinje Cell Dendritic Development via Lysyl Oxidase Propeptide and NF-Î°B Signaling. Neuron, 2010, 68, 45-60.	8.1	67
5	Measuring longitudinal myelin water fraction in new multiple sclerosis lesions. NeuroImage: Clinical, 2015, 9, 369-375.	2.7	58
6	Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens. Frontiers in Cellular and Infection Microbiology, 2017, 7, 11.	3.9	51
7	Relapses in multiple sclerosis: Relationship to disability. Multiple Sclerosis and Related Disorders, 2016, 6, 10-20.	2.0	36
8	Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. Nature, 2021, 600, 707-712.	27.8	35
9	Re-evaluating the treatment of acute optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 799-808.	1.9	29
10	Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Multiple Sclerosis and Related Disorders, 2017, 15, 27-33.	2.0	25
11	Carbon Monoxide Suppresses Membrane Expression of TLR4 via Myeloid Differentiation Factor-2 in Î²TC3 Cells. Journal of Immunology, 2010, 185, 2134-2139.	0.8	24
12	Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL. PLoS Pathogens, 2019, 15, e1008014.	4.7	21
13	Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans. Journal of Neuroimaging, 2017, 27, 333-338.	2.0	17
14	Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 540-542.	3.0	13
15	A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1907-1912.	2.2	11
16	Black African and Latino/a identity correlates with increased plasmablasts in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	11
17	Clostridium perfringens Epsilon Toxin Compromises the Blood-Brain Barrier in a Humanized Zebrafish Model. IScience, 2019, 15, 39-54.	4.1	10
18	A Novel Panel of Rabbit Monoclonal Antibodies and Their Diverse Applications Including Inhibition of Clostridium perfringens Epsilon Toxin Oligomerization. Antibodies, 2018, 7, 37.	2.5	8

#	Article	IF	Citations
19	Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions. Journal of Neuroimaging, 2020, 30, 537-543.	2.0	7
20	A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis. Molecular Imaging and Biology, 2020, 22, 1600-1608.	2.6	5
21	In vivo Blood-brain Barrier Permeability Assays Using Clostridium perfringens Epsilon Toxin. Bio-protocol, 2020, 10, e3709.	0.4	2
22	Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 553-554.	3.0	1